Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 2, 2015, Pages F131-F139

  Kim, Jinu ^a,b,c   Yoon, Sang Pil ^b   Toews, Myron L ^a   Imig, John D ^d   Hwang, Sung Hee ^e   Hammock, Bruce D ^e   Padanilam, Babu J ^a,f  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Jeju National University School of Medicine   (South Korea)

^c Jeju National University   (South Korea)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; Epoxyeicosatrienoic acid; Peroxisome proliferator activated receptor; Soluble epoxide hydrolase; Trans 4 4 3 (4 trifluoromethoxyphenyl)ureido cyclohexyloxy benzoic acid

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOATTRACTANT; COLLAGEN; HYDROLASE INHIBITOR; HYDROXYPROLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIPID HYDROPEROXIDE; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMAD3 PROTEIN; SYNAPTOTAGMIN I; TRANS 4 [4 [3 (4 TRIFLUOROMETHOXYPHENYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 4 [4 [3 (4 TRIFLUOROMETHOXYPHENYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; ENZYME INHIBITOR; EPOXIDE HYDROLASE; SOLUBLE EPOXIDE HYDROLASE; 4-(4-(3-(4-TRIFLUOROMETHOXY-PHENYL)UREIDO)CYCLOHEXYLOXY)BENZOIC ACID; ARACHIDONIC ACID DERIVATIVE; BENZOIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROGENESIS; KIDNEY; KIDNEY BLOOD FLOW; KIDNEY DEVELOPMENT; KIDNEY FIBROSIS; KIDNEY TUBULE DAMAGE; LIPID PEROXIDATION; MACROPHAGE; MALE; MOUSE; MYOFIBROBLAST; NEPHRITIS; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL INTERSTITIAL FIBROGENESIS; RENAL PROTECTION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; UNILATERAL URETERAL OBSTRUCTION; UPREGULATION; URETER OBSTRUCTION; ANIMAL TISSUE; DRUG EFFICACY; FIBROSING ALVEOLITIS; INFLAMMATION; KERATINOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; DRUG SCREENING; KIDNEY CIRCULATION; METABOLISM; NEPHROSCLEROSIS; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; ARACHIDONIC ACIDS; BENZOATES; BLOOD PRESSURE; CELL DEATH; DRUG EVALUATION, PRECLINICAL; EPOXIDE HYDROLASES; MALE; MICE, INBRED C57BL; NEPHROSCLEROSIS; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHENYLUREA COMPOUNDS; RENAL CIRCULATION; RENAL INSUFFICIENCY, CHRONIC; URETERAL OBSTRUCTION;

EID: 84921000088     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00531.2014     Document Type: Article

References (65)

1. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X; AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363: 918–929, 2010.
2. Bakris G, Vassalotti J, Ritz E, Wanner C, Stergiou G, Molitch M, Nesto R, Kaysen GA, Sowers JR. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int 78: 726–736, 2010.
3. Bellien J, Joannides R. Epoxyeicosatrienoic acid pathway in human health and diseases. J Cardiovasc Pharmacol 61: 188–196, 2013.
4. Boesen EI, Crislip GR, Sullivan JC. Use of ultrasound to assess renal reperfusion and P-selectin expression following unilateral renal ischemia. Am J Physiol Renal Physiol 303: F1333–F1340, 2012.
5. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 346: 371–374, 1990.
6. Borges FT, Melo SA, Ozdemir BC, Kato N, Revuelta I, Miller CA, Gattone VH, 2nd LeBleu VS, Kalluri R. TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol 24: 385–392, 2013.
7. Bottinger EP. TGF- β in renal injury and disease. Semin Nephrol 27: 309–320, 2007.
8. Chamberlain RM, Shirley DG. Time course of the renal functional response to partial nephrectomy: measurements in conscious rats. Exp Physiol 92: 251–262, 2007.
9. Chen JK, Capdevila J, Harris RC. Cytochrome P450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol 21: 6322–6331, 2001.
10. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75: 1145–1152, 2009.
11. Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 50: 225–237, 2007.
12. Decleves AE, Sharma K. Novel targets of antifibrotic and anti-inflammatory treatment in CKD. Nat Rev Nephrol 10: 257–267, 2014.
13. Dendooven A, Ishola DA Jr, Nguyen TQ, Van der Giezen DM, Kok RJ, Goldschmeding R, Joles JA. Oxidative stress in obstructive nephropathy. Int J Exp Pathol 92: 202–210, 2011.
14. Diano S, Liu ZW, Jeong JK, Dietrich MO, Ruan HB, Kim E, Suyama S, Kelly K, Gyengesi E, Arbiser JL, Belsham DD, Sarruf DA, Schwartz MW, Bennett AM, Shanabrough M, Mobbs CV, Yang X, Gao XB, Horvath TL. Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat Med 17: 1121–1127.
15. Djamali A. Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts. Am J Physiol Renal Physiol 293: F445–F455, 2007.
16. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock B., Imig JD. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-ylureido) dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 46: 842–848, 2005.
17. Elmarakby AA, Faulkner J, Al-Shabrawey M, Wang MH, Maddipati KR, Imig JD. Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin- induced type 1 diabetes. Am J Physiol Regul Integr Comp Physiol 301: R1307–R1317, 2011.
18. Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 52: 447–454, 2004.
19. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, Varga J. Peroxisome proliferator-activated receptor-γ abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 23: 2968–2977, 2009.
20. Guedes AG, Morisseau C, Sole A, Soares JH, Ulu A, Dong H, Hammock BD. Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis. Vet Anaesth Analg 40: 440–448, 2013.
21. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ 332: 563–564, 2006.
22. Han JY, Kim YJ, Kim L, Choi SJ, Park IS, Kim JM, Chu YC, Cha DR. PPAR γ agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis. J Korean Med Sci 25: 35–41, 2010.
23. Hogaboam CM, Steinhauser ML, Chensue SW, Kunkel SL. Novel roles for chemokines and fibroblasts in interstitial fibrosis. Kidney Int 54: 2152–2159, 1998.
24. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289: F496–F503, 2005.
25. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 92: 101–130, 2012.
26. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8: 794–805, 2009.
27. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7: 2364–2370, 1996.
28. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39: 690–694, 2002.
29. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46: 975–981, 2005.
30. Inoue T, Takenaka T, Hayashi M, Monkawa T, Yoshino J, Shimoda K, Neilson EG, Suzuki H, Okada H. Fibroblast expression of an IκB dominant-negative transgene attenuates renal fibrosis. J Am Soc Nephrol 21: 2047–2052, 2010.
31. Ishii N, Fujiwara K, Lane PH, Patel KP, Carmines PK. Renal cortical nitric oxide synthase activity during maturational growth in the rat. Pediatr Nephrol 17: 591–596, 2002.
32. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock B., Busse R, Fleming I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45: 759–765, 2005.
33. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, Kohno N, Yorioka N. PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF- β. Lab Invest 89: 47–58, 2008.
34. Kim J, Imig JD, Yang J, Hammock B., Padanilam BJ. Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. Am J Physiol Renal Physiol 307: F971–F980, 2014.
35. Kim J, Long KE, Tang K, Padanilam BJ. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int 82: 193–203, 2012.
36. Kim J, Padanilam BJ. Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction. Am J Physiol Renal Physiol 301: F450–F459, 2011.
37. Kim J, Padanilam BJ. Renal nerves drive interstitial fibrogenesis in obstructive nephropathy. J Am Soc Nephrol 24: 229–242, 2013.
38. Kim J, Seok YM, Jung KJ, Park KM. Reactive oxygen species/ oxidative stress contributes to progression of kidney fibrosis following transient ischemic injury in mice. Am J Physiol Renal Physiol 297: F461–F470, 2009.
39. Kim JC, Lee YH, Yu MK, Lee NH, Park JD, Bhattarai G, Yi HK. Anti-inflammatory mechanism of PPARγ on LPS-induced pulp cells: role of the ROS removal activity. Arch Oral Biol 57: 392–400, 2012.
40. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330: 877–884, 1994.
41. Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei Y, Sato N. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 291: 55–61, 2002.
42. Lee KSS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, Wulff H, Newcomer ME, Zeldin DC, Hammock BD. Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem 57: 7016–7030, 2014.
43. Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci 13: 3480–3487, 2008.
44. Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A, Eichinger F, Gaiser S, Schmid H, Rastaldi MP, Schrier RW, Schlondorff D, Cohen CD. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol 18: 1765–1776, 2007.
45. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock B., Shyy JY. The antiinflammatory effect of laminar flow: the role of PPAR γ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 102: 16747–16752, 2005.
46. Loch D, Hoey A, Morisseau C, Hammock B., Brown L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 47: 87–98, 2007.
47. Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG, Hammock BD. Soluble epoxide hydrolase deficiency alterspancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci USA 108: 9038–9043, 2011.
48. Ma LJ, Yang H, Gaspert A, Carlesso G, Barty MM, Davidson JM, Sheppard D, Fogo AB. Transforming growth factor-β-dependent and -independent pathways of induction of tubulointerstitial fibrosis in β 6-/- mice. Am J Pathol 163: 1261–1273, 2003.
49. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock B., Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 297: F740–F748, 2009.
50. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58: 2341–2350, 2000.
51. Mehal W, Imaeda A. Cell death and fibrogenesis. Semin Liver Dis 30: 226–231, 2010.
52. Ohmori Y, Fukumoto S, Hamilton TA. Two structurally distinct κB sequence motifs cooperatively control LPS-induced KC gene transcription in mouse macrophages. J Immunol 155: 3593–3600, 1995.
53. Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock B., Imig JD. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond) 116: 61–70, 2009.
54. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-β-independent mechanism. Circulation 111: 2509–2517, 2005.
55. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 102: 9772–9777, 2005.
56. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275: 40504–40510, 2000.
57. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology 17: 311–321, 2012.
58. Sullivan JC, Wang B, Boesen EI, D’Angelo G, Pollock JS, Pollock DM. Novel use of ultrasound to examine regional blood flow in the mouse kidney. Am J Physiol Renal Physiol 297: F228–F235, 2009.
59. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K, Fukushima J, Kawamoto S, Ishigatsubo Y, Okubo T. NF-κB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 153: 2052–2063, 1994.
60. Ulu A, Appt S, Morisseau C, Hwang SH, Jones PD, Rose TE, Dong H, Lango J, Yang J, Tsai HJ, Miyabe C, Fortenbach C, Adams MR, Hammock BD. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. Br J Pharmacol 165: 1401–1412, 2012.
61. Wang L, Yang J, Guo L, Uyeminami D, Dong H, Hammock B., Pinkerton KE. Use of a soluble epoxide hydrolase inhibitor in smokeinduced chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 46: 614–622, 2012.
62. Wang YX, Ulu A, Zhang LN, Hammock B. Soluble epoxide hydrolase in atherosclerosis. Curr Atheroscler Rep 12: 174–183, 2010.
63. Widmer U, Manogue KR, Cerami A, Sherry B. Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1α, and MIP-1β, members of the chemokine superfamily of proinflammatory cytokines. J Immunol 150: 4996–5012, 1993.
64. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, Davis BB, Low R, Hammock B., Chiamvimonvat N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103: 18733–18738, 2006.
65. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock B., Zeldin DC, Kroetz DL. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87: 992–998, 2000.